Published in J Pathol on June 01, 2009
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest (2012) 3.64
Comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancer. J Natl Cancer Inst (2014) 2.06
Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets. PLoS One (2010) 1.58
Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. J Natl Cancer Inst (2014) 1.58
curatedOvarianData: clinically annotated data for the ovarian cancer transcriptome. Database (Oxford) (2013) 1.40
Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. EMBO Mol Med (2013) 1.38
Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer. PLoS One (2012) 1.31
A seven-gene prognostic model for platinum-treated ovarian carcinomas. Br J Cancer (2011) 0.96
Pathway index models for construction of patient-specific risk profiles. Stat Med (2012) 0.93
Más-o-menos: a simple sign averaging method for discrimination in genomic data analysis. Bioinformatics (2014) 0.89
MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer. BMC Cancer (2014) 0.88
Single Gene Prognostic Biomarkers in Ovarian Cancer: A Meta-Analysis. PLoS One (2016) 0.87
TRRUST: a reference database of human transcriptional regulatory interactions. Sci Rep (2015) 0.87
WNT7A/β-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer. Oncogene (2014) 0.87
Machine learning methods in the computational biology of cancer. Proc Math Phys Eng Sci (2014) 0.87
Identification of candidate circulating cisplatin-resistant biomarkers from epithelial ovarian carcinoma cell secretomes. Br J Cancer (2013) 0.86
Prediction of resistance to chemotherapy in ovarian cancer: a systematic review. BMC Cancer (2015) 0.85
Engineered reversal of drug resistance in cancer cells--metastases suppressor factors as change agents. Nucleic Acids Res (2013) 0.83
Integrative analysis of cancer-related signaling pathways. Front Physiol (2013) 0.83
OvMark: a user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets. Mol Cancer (2014) 0.81
AKT in stromal fibroblasts controls invasion of epithelial cells. Oncotarget (2013) 0.81
Pilot study: alteration of deleted in liver cancer1 and phosphorylated focal adhesion kinase Y397 cytoplasmic expression and the prognostic value in advanced epithelial ovarian carcinoma. Int J Mol Sci (2011) 0.81
Elevated AKAP12 in paclitaxel-resistant serous ovarian cancer cells is prognostic and predictive of poor survival in patients. J Proteome Res (2015) 0.81
Suppression of GNAI2 message in ovarian cancer. J Ovarian Res (2014) 0.81
Stroma-associated master regulators of molecular subtypes predict patient prognosis in ovarian cancer. Sci Rep (2015) 0.80
Risk prediction model for epithelial ovarian cancer using molecular markers and clinical characteristics. J Ovarian Res (2015) 0.79
Extracting a low-dimensional description of multiple gene expression datasets reveals a potential driver for tumor-associated stroma in ovarian cancer. Genome Med (2016) 0.78
Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinoma. Gynecol Oncol (2015) 0.76
Optimized Prediction of Extreme Treatment Outcomes in Ovarian Cancer. Cancer Inform (2016) 0.75
Gene expression profiling of ovarian carcinomas and prognostic analysis of outcome. J Ovarian Res (2015) 0.75
The transcriptomic profile of ovarian cancer grading. Cancer Med (2014) 0.75
Expression signature distinguishing two tumour transcriptome classes associated with progression-free survival among rare histological types of epithelial ovarian cancer. Br J Cancer (2016) 0.75
Structured Matrix Completion with Applications to Genomic Data Integration. J Am Stat Assoc (2016) 0.75
The association between copper transporters and the prognosis of cancer patients undergoing chemotherapy: a meta-analysis of literatures and datasets. Oncotarget (2016) 0.75
multiClust: An R-package for Identifying Biologically Relevant Clusters in Cancer Transcriptome Profiles. Cancer Inform (2016) 0.75
NUAK1 (ARK5) Is Associated with Poor Prognosis in Ovarian Cancer. Front Oncol (2016) 0.75
A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med (2011) 8.63
Mucosal flora in inflammatory bowel disease. Gastroenterology (2002) 8.42
An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat (2009) 7.91
Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol (2009) 7.21
Slug and Sox9 cooperatively determine the mammary stem cell state. Cell (2012) 4.77
The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol (2012) 4.30
Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol (2013) 4.11
Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol (2010) 3.46
The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging (2014) 3.40
Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol (2008) 3.12
Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS One (2012) 2.85
HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch (2010) 2.72
Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res (2006) 2.68
Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol (2011) 2.56
Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. Cell Stem Cell (2011) 2.47
ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer. Eur Urol (2007) 2.40
Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res (2008) 2.36
CD24 expression is a new prognostic marker in breast cancer. Clin Cancer Res (2003) 2.15
Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer. Cancer (2008) 2.10
Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression. Cancer Res (2011) 2.07
Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. J Clin Oncol (2003) 2.04
Metabolite profiling of human colon carcinoma--deregulation of TCA cycle and amino acid turnover. Mol Cancer (2008) 2.02
An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. J Thorac Oncol (2014) 1.97
Fungi and inflammatory bowel diseases: Alterations of composition and diversity. Scand J Gastroenterol (2008) 1.89
Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol (2010) 1.85
Systemic presence and tumor-growth promoting effect of ovarian carcinoma released exosomes. Cancer Lett (2009) 1.84
The CHK2-BRCA1 tumour suppressor pathway ensures chromosomal stability in human somatic cells. Nat Cell Biol (2010) 1.81
Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene (2005) 1.80
Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression. Cancer Res (2004) 1.79
Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients. Acta Oncol (2011) 1.78
Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. Cancer Res (2009) 1.75
Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat (2010) 1.73
Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM. Gynecol Oncol (2007) 1.68
ErbB-3 predicts survival in ovarian cancer. J Clin Oncol (2006) 1.64
Solid neuroendocrine carcinomas of the breast: metastases or primary tumors? Breast Cancer Res Treat (2010) 1.63
Pseudo-pseudo Meigs' syndrome. Lancet (2005) 1.63
How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists. PLoS One (2012) 1.61
Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res (2008) 1.60
Expression of the ELAV-like protein HuR in human colon cancer: association with tumor stage and cyclooxygenase-2. Mod Pathol (2006) 1.59
A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer. Eur J Cancer (2009) 1.59
Expression of the ELAV-like protein HuR is associated with higher tumor grade and increased cyclooxygenase-2 expression in human breast carcinoma. Clin Cancer Res (2004) 1.58
Evaluation of microarray preprocessing algorithms based on concordance with RT-PCR in clinical samples. PLoS One (2009) 1.55
Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer (2003) 1.55
Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort. Mod Pathol (2010) 1.55
An illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity. Cancer Res (2010) 1.55
Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol (2006) 1.54
ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions. Prostate (2003) 1.54
Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer (2006) 1.53
A colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential. Gastroenterology (2009) 1.52
Contemporary management of endometrial cancer. Lancet (2012) 1.51
YB-1 as a cell cycle-regulated transcription factor facilitating cyclin A and cyclin B1 gene expression. J Biol Chem (2003) 1.51
Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. J Pathol (2005) 1.51
Magnetic nanoparticles for interstitial thermotherapy--feasibility, tolerance and achieved temperatures. Int J Hyperthermia (2006) 1.50
Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival. Clin Cancer Res (2005) 1.50
Long-term effects of neovaginal reconstruction with sigmoid loop technique on sexual function and self image in patients with gynecologic malignancies: results of a prospective study. Gynecol Oncol (2008) 1.48
Heterogeneous expression of Wnt/beta-catenin target genes within colorectal cancer. Int J Cancer (2007) 1.48
Polymorphisms of the endothelial nitric oxide synthase gene in breast cancer. Breast Cancer Res Treat (2006) 1.46
EGFR mutation detection in NSCLC--assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC. Virchows Arch (2010) 1.45
Quantitative determination of estrogen receptor, progesterone receptor, and HER2 mRNA in formalin-fixed paraffin-embedded tissue--a new option for predictive biomarker assessment in breast cancer. Diagn Mol Pathol (2011) 1.44
Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol Oncol (2006) 1.42
Choline-releasing glycerophosphodiesterase EDI3 drives tumor cell migration and metastasis. Proc Natl Acad Sci U S A (2012) 1.41
Noncompaction myocardium in association with type Ib glycogen storage disease. Pathol Res Pract (2012) 1.41
Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. Prostate (2004) 1.40
Prognostic relevance of AGR2 expression in breast cancer. Clin Cancer Res (2006) 1.40
KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology. J Mol Diagn (2009) 1.38
YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification. Cancer Res (2005) 1.37